ND Pharma & Biotech: e-TECNOWORK and Computational Chemistry
ND Pharma & Biotech operate and maintain a series of agreements with High-Tech Institutions and Centers Worldwide. Between them we are fortunate to count as partners a number of first-line, well-reputed professionals and technicians, commercial infrastructure and a complete team of entrepreneurship development. We call to this environment our e-TECHNOWORK.
e-TECHNOWORK is a comprehensive system of processing, management and combination of informational sources, both real and virtual to the consecution of our highest goals and objectives in health and human disease fight. We have created the e-LABS, e-MODELS, e-TRIALS and and other sources of electronic tools to optimize the use of information technologies and reach the top investigational levels available throughout these methods. All this is placed in conjoint with the classical and real mechanisms of R+D+i to experience and accomplish the higher levels of achievement ND Pharma & Biotech is reaching.
We invest in technology and science, we invest in talent, we invest in knowledge, we are making a clear strategy for the future, paving the way to the next generation researchers, building a no-boundaries world, conscious of the world boom ahead, an phenomenon without precedent that human beings are facing actually, something that for sure will last for decades up next.
e-TECHNOWORK is a comprehensive system of processing, management and combination of informational sources, both real and virtual to the consecution of our highest goals and objectives in health and human disease fight. We have created the e-LABS, e-MODELS, e-TRIALS and and other sources of electronic tools to optimize the use of information technologies and reach the top investigational levels available throughout these methods. All this is placed in conjoint with the classical and real mechanisms of R+D+i to experience and accomplish the higher levels of achievement ND Pharma & Biotech is reaching.
We invest in technology and science, we invest in talent, we invest in knowledge, we are making a clear strategy for the future, paving the way to the next generation researchers, building a no-boundaries world, conscious of the world boom ahead, an phenomenon without precedent that human beings are facing actually, something that for sure will last for decades up next.
Developing innovative therapies that address the source of disease, not just the symptoms
Solutions for managing complex human disease.
Our discovery and development platforms for drug and cell-based therapies allow us to create and retain significant value within our therapeutic areas of cancer and inflammatory diseases.
Our team of world-class scientists and physicians continue to expand and build on those platforms.
Scientists and physicians at our Research Affiliated Institutions are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.
These platforms encompass the key functions required to generate a broad, deep and diverse pipeline, including: cell biology, genomics, proteomics and informatics technologies for identifying and validating clinically important therapeutic targets; high-throughput screening systems combined with diverse and focused compound libraries for discovering new drug leads; computational and medicinal chemistry for optimizing drug candidates; in vitro and in vivo models of disease for preclinical evaluation of drug efficacy and safety; and a clinical and regulatory organization highly experienced in the successful development of pharmaceutical agents.
The progress that our company has made positions it to expand and accelerate the development of several high-potential compounds that have emerged from its rich discovery programs.
Solutions for managing complex human disease.
Our discovery and development platforms for drug and cell-based therapies allow us to create and retain significant value within our therapeutic areas of cancer and inflammatory diseases.
Our team of world-class scientists and physicians continue to expand and build on those platforms.
Scientists and physicians at our Research Affiliated Institutions are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.
These platforms encompass the key functions required to generate a broad, deep and diverse pipeline, including: cell biology, genomics, proteomics and informatics technologies for identifying and validating clinically important therapeutic targets; high-throughput screening systems combined with diverse and focused compound libraries for discovering new drug leads; computational and medicinal chemistry for optimizing drug candidates; in vitro and in vivo models of disease for preclinical evaluation of drug efficacy and safety; and a clinical and regulatory organization highly experienced in the successful development of pharmaceutical agents.
The progress that our company has made positions it to expand and accelerate the development of several high-potential compounds that have emerged from its rich discovery programs.
